Drug Profile
Alobresib - Gilead Sciences
Alternative Names: GS 5829Latest Information Update: 28 Oct 2022
Price :
$50
*
At a glance
- Originator Gilead Sciences
- Class Antineoplastics
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II HER2 negative breast cancer; Prostate cancer
- No development reported Breast cancer; Diffuse large B cell lymphoma; Lymphoma
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy, First-line therapy, Late-stage disease) in USA (PO, Tablet)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Diffuse large B cell lymphoma(Combination therapy) in USA (PO)
- 03 Sep 2019 Gilead Sciences completes a phase I/II trial in Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease, Monotherapy) in Belgium, USA (PO) (EudraCT2015-003741-26) (NCT02607228)